Skip to main content

Endometrial Cancer

News
11/05/2025
Grace Taylor, MS, MA
A qualitative study finds that culturally sensitive communication and education can increase Black women’s acceptance of a biopsy-first strategy to improve early endometrial cancer detection and reduce mortality disparities.
A qualitative study finds that culturally sensitive communication and education can increase Black women’s acceptance of a biopsy-first strategy to improve early endometrial cancer detection and reduce mortality disparities.
A qualitative study finds that...
11/05/2025
Journal of Clinical Pathways
News
12/17/2024
Juliet Gallagher
Metabolic disorders such as obesity and dyslipidemia are closely linked to diagnosis and risk of endometrial cancer (EC). With incidence and mortality rates on the rise, a study in Cell Communication and Signaling analyzed how lipid...
Metabolic disorders such as obesity and dyslipidemia are closely linked to diagnosis and risk of endometrial cancer (EC). With incidence and mortality rates on the rise, a study in Cell Communication and Signaling analyzed how lipid...
Metabolic disorders such as...
12/17/2024
Journal of Clinical Pathways
News
12/13/2024
Lisa Kuhns, PhD, MD
Patients with endometrial cancer who receive adjuvant radiation therapy (RT) may face an increased risk of developing certain second primary malignancies (SPMs).
Patients with endometrial cancer who receive adjuvant radiation therapy (RT) may face an increased risk of developing certain second primary malignancies (SPMs).
Patients with endometrial cancer...
12/13/2024
Journal of Clinical Pathways
News
12/06/2024
Lisa Kuhns, PhD, MD
A cutting-edge artificial intelligence (AI) model significantly improves the accuracy and efficiency of diagnosing high-risk endometrial cancer (EC) and predicting postoperative recurrence compared to traditional methods.
A cutting-edge artificial intelligence (AI) model significantly improves the accuracy and efficiency of diagnosing high-risk endometrial cancer (EC) and predicting postoperative recurrence compared to traditional methods.
A cutting-edge artificial...
12/06/2024
Journal of Clinical Pathways
News
11/27/2024
Danielle Sposato
According to a recent study published in JAMA Network Open, gynecological cancers in the US disproportionately impact marginalized racial and ethnic groups. Mortality rates for cervical, endometrial, and ovarian cancers are notably higher...
According to a recent study published in JAMA Network Open, gynecological cancers in the US disproportionately impact marginalized racial and ethnic groups. Mortality rates for cervical, endometrial, and ovarian cancers are notably higher...
According to a recent study...
11/27/2024
Journal of Clinical Pathways
News
11/27/2024
Danielle Sposato
Researchers explored the effectiveness of combination levatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, an anti-PD-1 monoclonal antibody, as a first-line treatment for advanced or recurrent EC. The combination of...
Researchers explored the effectiveness of combination levatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, an anti-PD-1 monoclonal antibody, as a first-line treatment for advanced or recurrent EC. The combination of...
Researchers explored the...
11/27/2024
Journal of Clinical Pathways
News
11/19/2024
Allison Casey
According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.
According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.
According to a phase 2 trial,...
11/19/2024
Oncology
From Oncology
News
11/13/2024
Hannah Musick
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with...
11/13/2024
Journal of Clinical Pathways
News
11/06/2024
Juliet Gallagher
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published...
11/06/2024
Journal of Clinical Pathways
News
10/25/2024
Grace Taylor, MS, MA
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and...
10/25/2024
Journal of Clinical Pathways
News
10/21/2024
Grace Taylor, MS, MA
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with...
10/21/2024
Journal of Clinical Pathways

Expert Insights

Steven Narod, MD, University of Toronto
Videos
09/12/2024
Steve Narod, MD, discusses the incidence of endometrial cancer among people who are BRCA mutation carriers.
Steve Narod, MD, discusses the incidence of endometrial cancer among people who are BRCA mutation carriers.
Steve Narod, MD, discusses the...
09/12/2024
Oncology
Bradley Corr, MD
Conference Coverage
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
David Barrington, MD
Videos
04/07/2022
David Barrington, MD, discusses a study that sought to describe national treatment patterns over time and examine associations between treatment modality and overall survival in patients with endometrioid endometrial carcinoma.
David Barrington, MD, discusses a study that sought to describe national treatment patterns over time and examine associations between treatment modality and overall survival in patients with endometrioid endometrial carcinoma.
David Barrington, MD, discusses...
04/07/2022
Journal of Clinical Pathways
David Barrington, MD
Videos
06/10/2021
David Barrington, MD, discusses results from a study suggesting lenvatinib plus pembrolizumab is not a cost-effective treatment option for patients with recurrent endometrial cancer.
David Barrington, MD, discusses results from a study suggesting lenvatinib plus pembrolizumab is not a cost-effective treatment option for patients with recurrent endometrial cancer.
David Barrington, MD, discusses...
06/10/2021
Journal of Clinical Pathways
Headshot of Joe DePinto
Interview
11/03/2026
Joe DePinto
In this interview, Joe DePinto discusses the growing adoption of cell and gene therapy in oncology care, focusing on tools and challenges providers, payers, and policymakers should be aware of when working to expand utilization among cancer...
In this interview, Joe DePinto discusses the growing adoption of cell and gene therapy in oncology care, focusing on tools and challenges providers, payers, and policymakers should be aware of when working to expand utilization among cancer...
In this interview, Joe DePinto...
11/03/2026
Journal of Clinical Pathways
Headshot of Dr Basu Roy
Interview
10/21/2026
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, discusses current challenges in treating non–small cell lung cancer (NSCLC) and explains how clinical pathways should evolve to focus on patient needs and experiences.
In this interview, Upal Basu Roy, PhD, MPH, discusses current challenges in treating non–small cell lung cancer (NSCLC) and explains how clinical pathways should evolve to focus on patient needs and experiences.
In this interview, Upal Basu...
10/21/2026
Journal of Clinical Pathways
Rob Helton
Interview
10/19/2026
Rob Helton, DPT
Rob Helton explores how intelligent medical records and integrated clinical decision support can streamline community oncology workflows, improve clinical pathway adherence, and reduce barriers to precision medicine.
Rob Helton explores how intelligent medical records and integrated clinical decision support can streamline community oncology workflows, improve clinical pathway adherence, and reduce barriers to precision medicine.
Rob Helton explores how...
10/19/2026
Journal of Clinical Pathways
Headshot of Dr Basu Roy
Interview
10/13/2026
Upal Basu Roy, PhD, MPH
In this interview, Upal Basu Roy, PhD, MPH, discusses improvements in the treatment landscape of non–small cell lung cancer (NSCLC) as well as ongoing research aimed at further enhancing disease management.
In this interview, Upal Basu Roy, PhD, MPH, discusses improvements in the treatment landscape of non–small cell lung cancer (NSCLC) as well as ongoing research aimed at further enhancing disease management.
In this interview, Upal Basu...
10/13/2026
Journal of Clinical Pathways
Gary Simmons, DO, MSHA
Interview
09/29/2026
Gary L. Simmons, DO
Gary L. Simmons, DO, MSHA, discusses Virginia Oncology Associates’ experience delivering CAR T-cell therapy in the community and how community-based programs can expand patient access while supporting safe delivery, care coordination, and...
Gary L. Simmons, DO, MSHA, discusses Virginia Oncology Associates’ experience delivering CAR T-cell therapy in the community and how community-based programs can expand patient access while supporting safe delivery, care coordination, and...
Gary L. Simmons, DO, MSHA,...
09/29/2026
Journal of Clinical Pathways
Nikki Martin Headshot
Interview
09/18/2026
Nikki Martin, MA
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin,...
09/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
08/18/2026
Kelsey Pan, MD
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses...
08/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
08/18/2026
Kelsey Pan, MD
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan,...
08/18/2026
Journal of Clinical Pathways
Deirdre Saulet, PhD
Blog
07/14/2026
Deirdre Saulet, PhD
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026...
07/14/2026
Journal of Clinical Pathways
B-cell lymphoma
Videos
07/06/2026
Paolo Strati, MD
Paolo Strati, MD, discusses how findings from the ZUMA-14 trial could shape the future of dual-targeting CAR T-cell therapy, treatment sequencing, and minimal residual disease monitoring in relapsed or refractory large B-cell lymphoma.
Paolo Strati, MD, discusses how findings from the ZUMA-14 trial could shape the future of dual-targeting CAR T-cell therapy, treatment sequencing, and minimal residual disease monitoring in relapsed or refractory large B-cell lymphoma.
Paolo Strati, MD, discusses how...
07/06/2026
Journal of Clinical Pathways

Newsfeed

News
11/05/2025
Grace Taylor, MS, MA
A qualitative study finds that culturally sensitive communication and education can increase Black women’s acceptance of a biopsy-first strategy to improve early endometrial cancer detection and reduce mortality disparities.
A qualitative study finds that culturally sensitive communication and education can increase Black women’s acceptance of a biopsy-first strategy to improve early endometrial cancer detection and reduce mortality disparities.
A qualitative study finds that...
11/05/2025
Journal of Clinical Pathways
News
12/17/2024
Juliet Gallagher
Metabolic disorders such as obesity and dyslipidemia are closely linked to diagnosis and risk of endometrial cancer (EC). With incidence and mortality rates on the rise, a study in Cell Communication and Signaling analyzed how lipid...
Metabolic disorders such as obesity and dyslipidemia are closely linked to diagnosis and risk of endometrial cancer (EC). With incidence and mortality rates on the rise, a study in Cell Communication and Signaling analyzed how lipid...
Metabolic disorders such as...
12/17/2024
Journal of Clinical Pathways
News
12/13/2024
Lisa Kuhns, PhD, MD
Patients with endometrial cancer who receive adjuvant radiation therapy (RT) may face an increased risk of developing certain second primary malignancies (SPMs).
Patients with endometrial cancer who receive adjuvant radiation therapy (RT) may face an increased risk of developing certain second primary malignancies (SPMs).
Patients with endometrial cancer...
12/13/2024
Journal of Clinical Pathways
News
12/06/2024
Lisa Kuhns, PhD, MD
A cutting-edge artificial intelligence (AI) model significantly improves the accuracy and efficiency of diagnosing high-risk endometrial cancer (EC) and predicting postoperative recurrence compared to traditional methods.
A cutting-edge artificial intelligence (AI) model significantly improves the accuracy and efficiency of diagnosing high-risk endometrial cancer (EC) and predicting postoperative recurrence compared to traditional methods.
A cutting-edge artificial...
12/06/2024
Journal of Clinical Pathways
News
11/27/2024
Danielle Sposato
According to a recent study published in JAMA Network Open, gynecological cancers in the US disproportionately impact marginalized racial and ethnic groups. Mortality rates for cervical, endometrial, and ovarian cancers are notably higher...
According to a recent study published in JAMA Network Open, gynecological cancers in the US disproportionately impact marginalized racial and ethnic groups. Mortality rates for cervical, endometrial, and ovarian cancers are notably higher...
According to a recent study...
11/27/2024
Journal of Clinical Pathways
News
11/27/2024
Danielle Sposato
Researchers explored the effectiveness of combination levatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, an anti-PD-1 monoclonal antibody, as a first-line treatment for advanced or recurrent EC. The combination of...
Researchers explored the effectiveness of combination levatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, an anti-PD-1 monoclonal antibody, as a first-line treatment for advanced or recurrent EC. The combination of...
Researchers explored the...
11/27/2024
Journal of Clinical Pathways
News
11/19/2024
Allison Casey
According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.
According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.
According to a phase 2 trial,...
11/19/2024
Oncology
News
11/13/2024
Hannah Musick
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with...
11/13/2024
Journal of Clinical Pathways
News
11/06/2024
Juliet Gallagher
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published...
11/06/2024
Journal of Clinical Pathways
News
10/25/2024
Grace Taylor, MS, MA
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and...
10/25/2024
Journal of Clinical Pathways
News
10/14/2026
Grace Taylor, MS, MA
A nationwide study found that insurance restrictions and high out-of-pocket costs prevent many patients with blood cancers from filling prescribed oral anticancer medications, even after insurer approval.
A nationwide study found that insurance restrictions and high out-of-pocket costs prevent many patients with blood cancers from filling prescribed oral anticancer medications, even after insurer approval.
A nationwide study found that...
10/14/2026
Journal of Clinical Pathways
News
10/09/2026
Rebecca Amrick
In the Enhancing Oncology Model (EOM) Lung Patient Pilot program, nurse outreach was associated with reduced emergency care utilization and health care spending among patients with metastatic lung cancer.
In the Enhancing Oncology Model (EOM) Lung Patient Pilot program, nurse outreach was associated with reduced emergency care utilization and health care spending among patients with metastatic lung cancer.
In the Enhancing Oncology Model...
10/09/2026
Journal of Clinical Pathways
News
09/29/2026
Rebecca Amrick
Protocol 2 of the MYLUNG study found that improvements in biomarker testing rates increased rates of targeted first-line therapies among patients with metastatic non–small cell lung cancer (mNSCLC), illustrating how biomarker testing can...
Protocol 2 of the MYLUNG study found that improvements in biomarker testing rates increased rates of targeted first-line therapies among patients with metastatic non–small cell lung cancer (mNSCLC), illustrating how biomarker testing can...
Protocol 2 of the MYLUNG study...
09/29/2026
Journal of Clinical Pathways
News
09/28/2026
Grace Taylor, MS, MA
A study found that comprehensive molecular profiling was associated with improved survival and reduced health care utilization among patients with non–small cell lung cancer (NSCLC), yet fewer than 1 in 15 patients underwent testing.
A study found that comprehensive molecular profiling was associated with improved survival and reduced health care utilization among patients with non–small cell lung cancer (NSCLC), yet fewer than 1 in 15 patients underwent testing.
A study found that comprehensive...
09/28/2026
Journal of Clinical Pathways
News
09/17/2026
Rebecca Amrick
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the...
09/17/2026
Journal of Clinical Pathways
News
09/08/2026
Rebecca Amrick
Researchers found that providing financial assistance for cancer patients with unmet social needs was associated with improvements in radiotherapy completion, indicating a potential strategy to promote health equity and reduce care gaps.
Researchers found that providing financial assistance for cancer patients with unmet social needs was associated with improvements in radiotherapy completion, indicating a potential strategy to promote health equity and reduce care gaps.
Researchers found that providing...
09/08/2026
Journal of Clinical Pathways
News
09/03/2026
Rebecca Amrick
Researchers found that testing for molecular biomarkers in patients with endometrial cancer is associated with prolonged survival and lower incremental costs than no testing, illustrating the importance of molecular classification in...
Researchers found that testing for molecular biomarkers in patients with endometrial cancer is associated with prolonged survival and lower incremental costs than no testing, illustrating the importance of molecular classification in...
Researchers found that testing...
09/03/2026
Journal of Clinical Pathways
News
08/31/2026
Rebecca Amrick
Researchers found that rituximab biosimilars were associated with similar health outcomes and lower care costs than originator rituximab when used to treat patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Researchers found that rituximab biosimilars were associated with similar health outcomes and lower care costs than originator rituximab when used to treat patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Researchers found that rituximab...
08/31/2026
Journal of Clinical Pathways
News
08/24/2026
Rebecca Amrick
A study found that longer hospitalizations were associated with higher care costs among patients with MM initiating treatment with bispecific antibodies, raising concerns about care delivery and access.
A study found that longer hospitalizations were associated with higher care costs among patients with MM initiating treatment with bispecific antibodies, raising concerns about care delivery and access.
A study found that longer...
08/24/2026
Journal of Clinical Pathways
News
08/17/2026
Rebecca Amrick
A study found that the presence of cytopenia was associated with poor survival outcomes in patients with myelofibrosis, suggesting cytopenia as a prognostic marker to monitor during disease management.
A study found that the presence of cytopenia was associated with poor survival outcomes in patients with myelofibrosis, suggesting cytopenia as a prognostic marker to monitor during disease management.
A study found that the presence...
08/17/2026
Journal of Clinical Pathways

Conference Coverage

Conference Coverage
09/12/2024
Allison Casey
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology
Bradley Corr, MD
Conference Coverage
03/21/2024

Featuring Bradley Corr, MD

Featuring Bradley Corr, MD
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting on Women’s Cancers, Bradley Corr, MD, discusses the results from a study evaluating rucaparib maintenance therapy for patients with metastatic or recurrent endometrial cancer.
At the 2024 SGO Annual Meeting...
03/21/2024
Oncology
News
03/19/2024
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and colleagues investigated the cost-effectiveness of immunotherapy regimes in upfront treatment with chemotherapy for patients with endometrial cancer.
Alex Francoeur, MD, and...
03/19/2024
Journal of Clinical Pathways
Conference Coverage
04/22/2021
Real-World Tolerability of PARP Inhibitors for Ovarian Cancer in the United States A study presented at the virtual 2021 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer compared the...
Real-World Tolerability of PARP Inhibitors for Ovarian Cancer in the United States A study presented at the virtual 2021 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer compared the...
...
04/22/2021
Journal of Clinical Pathways
Conference Coverage
11/12/2026
Hannah Musick
At CPC 2026, oncology leaders explored how AI, precision medicine, and expanding cell and gene therapies are transforming clinical pathways, emphasizing the importance of coordinated care delivery, physician oversight, and improved patient...
At CPC 2026, oncology leaders explored how AI, precision medicine, and expanding cell and gene therapies are transforming clinical pathways, emphasizing the importance of coordinated care delivery, physician oversight, and improved patient...
At CPC 2026, oncology leaders...
11/12/2026
Journal of Clinical Pathways
Conference Coverage
11/12/2026
Hannah Musick
At CPC 2026, oncology leaders explored how integrated clinical pathways, value-based contracting, and shared savings models can align financial incentives with quality care, reduce administrative barriers, and improve patient access.
At CPC 2026, oncology leaders explored how integrated clinical pathways, value-based contracting, and shared savings models can align financial incentives with quality care, reduce administrative barriers, and improve patient access.
At CPC 2026, oncology leaders...
11/12/2026
Journal of Clinical Pathways
Conference Coverage
11/11/2026
Rebecca Amrick
Panelists at the Clinical Pathways Congress 2026 discussed how payers and physicians can work together to reduce PA-related burdens and improve direct communication to promote patient-centered care.
Panelists at the Clinical Pathways Congress 2026 discussed how payers and physicians can work together to reduce PA-related burdens and improve direct communication to promote patient-centered care.
Panelists at the Clinical...
11/11/2026
Journal of Clinical Pathways
Conference Coverage
11/11/2026
Rebecca Amrick
Panelists at the Clinical Pathways Congress 2026 explored the dynamics between health policy and legislation and how evolutions in utilization management may impact patient care and pathway development.
Panelists at the Clinical Pathways Congress 2026 explored the dynamics between health policy and legislation and how evolutions in utilization management may impact patient care and pathway development.
Panelists at the Clinical...
11/11/2026
Journal of Clinical Pathways
Conference Coverage
11/11/2026
Hannah Musick
Oncology leaders discussed strategies for incorporating patient preferences, financial hardship, and social barriers into clinical pathway development, highlighting the potential of navigation services, shared decision-making, and AI to...
Oncology leaders discussed strategies for incorporating patient preferences, financial hardship, and social barriers into clinical pathway development, highlighting the potential of navigation services, shared decision-making, and AI to...
Oncology leaders discussed...
11/11/2026
Journal of Clinical Pathways
Conference Coverage
11/11/2026
Grace Taylor, MS, MA
At the 2026 Clinical Pathways Congress, experts explored how pharmaceutical collaboration, real-world evidence, and artificial intelligence could advance adaptive oncology clinical pathways and support more personalized, value-based cancer...
At the 2026 Clinical Pathways Congress, experts explored how pharmaceutical collaboration, real-world evidence, and artificial intelligence could advance adaptive oncology clinical pathways and support more personalized, value-based cancer...
At the 2026 Clinical Pathways...
11/11/2026
Journal of Clinical Pathways
Conference Coverage
11/11/2026
Rebecca Amrick
At the Clinical Pathways Congress 2026, expert panelists discussed the value of individualized care within pathway development and governance, with providers basing treatment decisions on patient needs, preferences, and outcomes.
At the Clinical Pathways Congress 2026, expert panelists discussed the value of individualized care within pathway development and governance, with providers basing treatment decisions on patient needs, preferences, and outcomes.
At the Clinical Pathways...
11/11/2026
Journal of Clinical Pathways
Conference Coverage
11/11/2026
Hannah Musick
At Clinical Pathways Congress 2026, the Predictable Cost of Care Working Group highlighted advances in AI-supported oncology economic modeling, demonstrating how standardized estimates of treatment-related costs could improve regimen...
At Clinical Pathways Congress 2026, the Predictable Cost of Care Working Group highlighted advances in AI-supported oncology economic modeling, demonstrating how standardized estimates of treatment-related costs could improve regimen...
At Clinical Pathways Congress...
11/11/2026
Journal of Clinical Pathways
Conference Coverage
11/10/2026
Rebecca Amrick
At the Clinical Pathways Congress 2026, guest speakers Carole Tremonti, RN, MBA, and Deirdre Saulet, PhD, discussed how artificial intelligence (AI) can improve the value of pathways among oncologists by organizing patient and trial data and...
At the Clinical Pathways Congress 2026, guest speakers Carole Tremonti, RN, MBA, and Deirdre Saulet, PhD, discussed how artificial intelligence (AI) can improve the value of pathways among oncologists by organizing patient and trial data and...
At the Clinical Pathways...
11/10/2026
Journal of Clinical Pathways
Conference Coverage
11/10/2026
Rebecca Amrick
At the Clinical Pathways Congress 2026, keynote speaker Ed Rodgers explored how patient participation, equity analyses, and individualized cost information can support informed treatment decisions and improve clinical pathways in oncology.
At the Clinical Pathways Congress 2026, keynote speaker Ed Rodgers explored how patient participation, equity analyses, and individualized cost information can support informed treatment decisions and improve clinical pathways in oncology.
At the Clinical Pathways...
11/10/2026
Journal of Clinical Pathways